Kornimate/medical-research-clean huggingface dataset:
effects of repeated memory training on memory function and addiction related processes

Conditions: Substance-Related Disorders

Summary: prospective memory is the ability to implement an intention to the future (e.g. remember to take medication, attend a scheduled meeting), and has receive little attention in addiction. the investigators propose that prospective memory plays a critical, yet unrecognized, role in major human behavior change such as that required in addiction treatment. this study will determine the preliminary efficacy of prospective memory training in improving memory and executive functions while reducing illicit drug use in methadone patients. participants will be randomly assigned to one of three conditions: an experimental memory training program or one of two comparator memory training programs.


Eligibility criteria:
inclusion criteria: * age 18-55; provision of written consent * enrolled in a substance use treatment program * sex with ≥ 2 partners in the last 30 days and sex without a condom on at least one occasion in the last year exclusion criteria: * severe psychiatric conditions associated with psychosis or any unstable psychiatric condition * history of medical, psychiatric, or neurological conditions associated with significant cognitive impairment

Keywords: prospective memory, working memory, substance abuse
can 3d ultrasound be used reproducibly by radiation therapists in partial breast image-guided radiation therapy

Conditions: Radiation Therapy for Primary Breast Cancer

Summary: to determine if the clarity 3dus (3d ultrasound) system can be used by multiple individuals to acquire 3dus images and produce consistent tb (tumor bed) shifts for breast igrt (image-guided radiation therapy).

tb contouring the ct1, ct2, and us1 tumor beds will be manually contoured on the rm workstation by one of the study radiation therapists. contouring will be performed using previously defined contouring guidelines. available automatic contouring tools, including the 'interpolate' contouring function, may be utilized and contouring times will be recorded. igrt assessment the patient will be set up on the breast board in treatment position. the 'ultra path' component of the clarity system, which displays the path of the previous us acquired at ct simulation, will be used to guide the acquisition of us2. although performed in the simulator room, the clarity system will be used in 'treatment mode' thus simulating clarity as it is used for igrt. the study rt will first acquire the us2 scan. all steps following the acquisition of us2 will be performed off-line on the rm workstation without the need for further simulator or patient time.

Eligibility criteria:
inclusion criteria: * subjects will be 27 consenting women undergoing ct simulation for adjuvant breast radiotherapy at vic ≤16 weeks after bcs. * women must have primary tumors \<3cm, pathologically n0 disease, and negative surgical margins. * seroma clarity score \<2 exclusion criteria: * patients will be excluded if they have had mastectomy or receive adjuvant chemotherapy that results in the ct simulation session occurring \>16 weeks after the bcs date.
conformal sphincter-preservation operation versus intersphincteric resection on anal function in low rectal cancer

Conditions: Rectum Cancer

Summary: in this clinical trial, the investigators compared anal function, genitourinary function, quality of life, perioperative safety, and oncological prognosis after cspo for patients with low rectal cancer, using isr as a control, to provide high-level evidence-based medical evidence for the choice of anorectal preservation surgical approaches for patients with low rectal cancer.

the cspo surgical approach is a series of targeted improvements designed primarily on the basis of analyzing the causes of poor postoperative function of the isr, while building on research on the ultrastructure of the pelvic floor anal canal. for these reasons, the investigators designed the present study to compare anal function, quality of life, perioperative safety, and oncologic prognosis after cspo for patients with low rectal cancer, using isr surgery as a control, and to provide high-level evidence-based medical evidence for the choice of anorectal preservation surgical modalities for patients with low rectal cancer.

Eligibility criteria:
inclusion criteria: 1. age: 18-75 years; 2. pathologically confirmed: moderately \& well-differentiated rectal cancer; 3. low rectal cancer: lower edge of tumor ≦5cm from anal verge or ≦2cm from dentate line; 4. tumor diameter: ≤3cm or \<1/3 bowel circumference; 5. tumor infiltration depth: ct1-2, bordeaux/rullier classification: type ii-iii; 6. locally progressive rectal cancer (ct1-4n0-2m0): significant tumor downstaging and downgrading after preoperative neoadjuvant therapy, meeting the above criteria; 7. asa score: i-iii and ecog score: 0-1; 8. undergo elective tme for colorectal or colorectal-anal canal anastomosis; 9. normal preoperative anal function: wexner score \<10, lars score \<20; 10. agree to participate in the clinical trial and sign an informed consent form. exclusion criteria: 1. combination of synchronous or metachronous (within 5 years) malignant tumors; 2. combined distant metastasis of the tumor; 3. combined intestinal obstruction, intestinal perforation, or intestinal bleeding requiring emergency surgery; 4. combined psychiatric disorders that do not allow them to understand and participate in the study; 5. combined systemic diseases that cannot tolerate surgery; 6. women who are pregnant or breastfeeding; 7. other reasons, judged by the investigator, for not being suitable for participation in this clinical trial.

Keywords: low rectum cancer cspo isr anal function
correlation of ultrasonography indices of venous congestion with intra-abdominal pressure in icu patients.

Conditions: Intra-Abdominal Hypertension; Venous Congestion

Summary: the goal of this prospective observational study is to examine the potential association between intra-abdominal pressure and venous congestion as assessed by abdominal ultrasound, in critically ill patients in the intensive care unit (icu). the main question it aims to answer is whether there is association between intra-abdominal pressure and venous excess ultrasound (vexus) score. participants will be sonographically assessed and their intra-abdominal pressure measured once within the first 3 days of icu admission.


Eligibility criteria:
inclusion criteria: * intubated icu patients on controlled mechanical ventilation, receiving sedation. patients must have urethral catheter in place. exclusion criteria: * age \< 18 year old * pregnancy / lactation * primary liver disease (hepatic cirrhosis, hepatic space-occupying lesions, budd-chiari syndrome, portal vein thrombosis) or hepatic surgery * end stage renal failure or on chronic dialysis * non-intubated patients or intubated patients on non-controlled mechanical ventilation mode * absence of urethral catheter, presence of suprapubic catheter, continuous bladder irrigation * poor abdominal echogenicity
thyroid disease diagnosis by mutiple ultrasonic factors.

Conditions: Thyroid; Nodule; Diagnoses Disease

Summary: in the outpatient clinic based population setting, the investigators want to reappraise the accuracy of the new model of multi-factorial ultrasound diagnosis with the conventional fine-needle aspiration cytology.

4 to 7 percent of adult population has a palpable thyroid nodule and 17% to 27% of cases can be found when examined by sonography. although the incidence of the thyroid nodules is high, only 1 of 20 clinically identified nodules is malignant. several gray scale sonographic characteristics have been suggestive of malignancy, including hypoechoigenicity, micro calcification, blurred margin and intranodular vascularity. the intranodular vascularity has been studied in several researches. but the previous studies usually evaluated the vascularity by color doppler sonography and only divided into several categories subjectively. and the result is controversial. the evaluation of the tumor microcirculation by doppler ultrasound has been used in many tumors and defined as vascularity index (vi). the power doppler sonography has many advantages over color doppler ultrasound in studying the vascularity. it is more sensitive, less noisy. power doppler can detect the blood flow of small internal tumor vessels with a diameter of less than 100μm at slow flow rates on the order of a few mm per second1,2 according to our previous study, the vascularity index(pdvi) of thyroid tumor by power doppler ultrasound between benign and malignant one are statistically different. in the present study, the investigators examine different pdvi of thyroid tumors and the traditional（b-mode）ultrasound features including the heterogeneity, echogenicity, margin status, and the presence of microcalcification. the investigators consider the several factors simultaneously by statistical model (pca, fld). in the outpatient clinic based population setting, the investigators want to reappraise the accuracy of the new model of multi-factorial ultrasound diagnosis with the conventional fine-needle aspiration cytology.

Eligibility criteria:
inclusion criteria: * patients who have discrete solid thyroid tumors need to undergo fine-needle aspiration cytology to provide the tentative diagnosis * discrete thyroid tumors with mainly solid content (\>50% solid content) and diameter of tumors between 0.5-3cm exclusion criteria: * abnormal thyroid function, past history of thyroiditis, multinodular goiter, and cystic tumors.
a prospective observational study of clinical outcomes for the nanostring® technologies prosigna™ gene signature assay

Conditions: Breast Cancer

Summary: the primary objective of this study is to assess the extent to which the prosigna™ breast cancer prognostic gene signature assay affects the medical oncologist's treatment recommendations regarding adjuvant chemotherapy and actual treatments received for patients with early-stage breast cancer.

changes in treatment recommendations will include (1) hormonal therapy alone, (2) hormonal therapy plus chemotherapy, and (3) changes in types of chemotherapy if chemotherapy was recommended before and after the test.

Eligibility criteria:
inclusion criteria: * resected node-negative, estrogen-receptor-positive, her2-negative early- stage invasive breast cancer (t1-t2, n0, pn0 (i+), pn0 (mol+), m0) * estrogen receptor status will be evaluated by immunohistochemistry (ihc) and more than 1% of stained tumor cells will be considered positive. * her2 status will be evaluated by ihc (0 or 1+, or 2+ will be considered negative) and by in-situ fluorescence hybridization. * postmenopausal women defined as: * natural amenorrhea \> 12 months, regardless of age * bilateral oophorectomy, regardless of age (the oophorectomy must have been carried out at least 4 weeks before entering the study) * radiological castration with amenorrhea \> 3 months, regardless of age * hysterectomy and postmenopausal blood levels * able to give consent * eligible for treatment of breast cancer with adjuvant chemotherapy * ecog performance status of 0 or 1 exclusion criteria: * tumor size t3-t4 * non-invasive breast cancer (e.g., paget's disease, dcis) * tumors with nodes that are not n0, pn0 (i+), or pn0 (mol+) * tumors that are estrogen-receptor negative or her2 positive * have metastatic disease * unable to give informed consent * unable to complete patient reported outcome surveys * have contraindications for adjuvant chemotherapy * age, performance status, significant comorbidities * ecog performance status \> 1
functional neuroimaging effects of cognitive remediation training

Conditions: Schizophrenia

Summary: the purpose of this study is to examine behavioral and functional brain changes occuring as a result of cognitive remediation training in patients with schizophrenia. extension and specificity of related changes will also be examined.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * stable outpatient exclusion criteria: * current drug abuse or dependence * history of neurological damage, disorder, or disease
afatinib and selumetinib in advanced kras mutant and pik3ca wildtype non-small cell lung cancer

Conditions: Colorectal Neoplasms; Gastrointestinal Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung

Summary: this is a multi-center open-label proof-of-concept study consisting of two parts: part a - a phase i dose-finding study (3 + 3 classical design) evaluating the rp2d of afatinib in combination with selumetinib in krasm nsclc; and part b - a randomized phase ii study investigating the progression free survival and safety of selumetinib/afatinib combination therapy compared to standard of care chemotherapy in krasm nsclc.


Eligibility criteria:
inclusion criteria: * histological or cytological proof of advanced nsclc; for part b: treated with first line therapy for metastatic disease only. * written documentation of a known pathogenic kras (exon 2, 3 or 4) mutation and pik3ca wildtype (defined as absence of mutations in exon 9 and 20) * able and willing to give written informed consent * able and willing to undergo blood sampling for pk and pd analysis * life expectancy \>=3 months allowing adequate follow up of toxicity evaluation and antitumor activity. * who performance status of 0 or 1. * able and willing to undergo a tumor biopsies prior to start, after two weeks (part a only) and upon progression of disease * measurable disease according to recist 1.1 * adequate organ system function measured by laboratory values exclusion criteria: * any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment. * history of another malignancy exception part a: patients who have been disease-free for at least 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent second malignancies are eligible. exception part b: adequately treated carcinoma in situ of the cervix and adequately treated basal cell carcinoma of the skin. 3. symptomatic or untreated leptomeningeal disease. * symptomatic brain metastasis. * patients previously treated with any drug combination known to interfere with egfr, her2, her3, her4 or mapk- and pi3k-pathway components, including inhibitors of pten, pi3k, akt, mtor, braf, mek and erk. * history of interstitial lung disease or pneumonitis * radio-, immuno- or chemotherapy within the last 2 weeks prior to receiving the first dose of investigational treatment. palliative radiation (1x 8gy) is allowed. * opthalmological diseases * patients with left ventricular ejection fraction (lvef) \< 55% * patients with cardiac comorbidities * concomitant or recent use (in the past 14 days) of strong inhibitors and inducers of cyp1a2, cyp2c19, cyp3a4, 3a5 and p-glycoprotein (p-gp)
effects of leaf extract of azadirachta indica in palmer arsenical keratosis

Conditions: Arsenical Keratosis

Summary: effects of leaf extract of azadirachta indica in palmer arsenical keratosis: randomized, double-blind, placebo-control trial

the objective of this study is to evaluate the effectiveness of topical administration of the leaf of azadirachta indica in the treatment of palmer arsenical keratosis. fifty patients of moderate palmer arsenical keratosis patients from an arsenic affected area will be recruited on the basis of inclusion and exclusion criteria and had been drinking arsenic contaminated water for more than six months. they will be divided into two groups each will consist of twenty five members. one group will be provided a. indica plus 6% salicylic acid ointment to apply on palm overnight daily for 12 weeks. another group will be provided 6% salicylic acid ointment . water and nail sample will be collected before starting recruitment to confirm diagnosis. then again nail sample will be collected before and after the study to see the level of arsenic in skin. effects will be observed after every two weeks and change will be detected as nil, mild reduction, moderate reduction and fully cured.

Eligibility criteria:
inclusion criteria: * palmer arsenical keratosis * drinking arsenic contaminated water (\>50 ppb) for more than six months * patient voluntarily agree to participate exclusion criteria: * pregnancy * lactating mother * diabetes mellitus * rheumatoid arthritis * systemic lupus erythematosus * psoriasis * bowen's disease

Keywords: palm arsenic keratosis salicylic acid azadirachta indica neem
dysregulated tyrosine kinase signaling in leukemia

Conditions: Leukemia

Summary: dysregulated tyrosine kinase signaling in leukemia

purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. these proteins make a cell grow or prevent the cell from dying

Eligibility criteria:
inclusion criteria: * patients must have newly diagnosed or relapsed leukemia. * patients must sign an informed consent. * patients will not be excluded if they are receiving chemotherapy. * patients with cml, aml, all, t/nk leukemia, myelodysplasia, or myeloproliferative disorders will be eligible. * patients must be =\> 18 years of age.

Keywords: leukemia
a study to evaluate the efficacy and safety of imsidolimab (anb019) in the treatment of participants with ichthyosis

Conditions: Ichthyosis

Summary: efficacy and safety of imsidolimab in participants with ichthyosis

this is a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in adolescent and adult participants with ichthyosis. this study will also characterize the pharmacokinetic (pk) profile of imsidolimab and explore the immune response to imsidolimab in participants with ichthyosis.

Eligibility criteria:
inclusion criteria: * diagnosis of ichthyosis * iasi total score ≥ 18, erythema score ≥ 2 * participant has been using emollient daily for at least 1 week prior to day 1 and agrees to continue using that same emollient daily at the same frequency throughout the study exclusion criteria: * a participant with ichthyosis vulgaris, x-linked ichthyosis, or lamellar ichthyosis will be excluded.

Keywords: il-36 receptor interleukin 36 imsidolimab
prospective cohort of patients with intracerebral hemorrhage

Conditions: Stroke, Acute; Intracerebral Hemorrhage

Summary: the investigators designed a multicentral, observational, prospective cohort study to provide cortical data for risk stratification and biomarkers on early outcomes, complications, long-term neurological function, and cognitive status of spontaneous intracerebral hemorrhage patients.


Eligibility criteria:
inclusion criteria: * diagnosed with spontaneous intracerebral hemorrhage (ich) through skull radiologic scans (ct or mri); * underwent no surgical intervention; exclusion criteria: * secondary intracerebral hemorrhage (with leading cause, e.g., moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma) * pre-stroke life expectancy \&lt; 1 year for severe comorbidities (e.g., progressive malignant tumor, severe chronic heart failure \[nyha: iii-iv\], severe chronic obstructive pulmonary disease \[iii-iv\], chronic kidney disease requiring hemodialysis) * severe dependency or incorporation to interview (e.g., pre-stroke mrs\&gt;3, severe dementia, intractable mental disease) * unsuitable for inclusion in the study in the opinion of the investigator

Keywords: intracerebral hemorrhage
collection of biospecimen & clinical information in patients w/ gastrointestinal cancers

Conditions: Gastrointestinal Neoplasms; Gynecologic Cancers; Gynecologic Cancers Cervical Cancer; Gastric (Stomach) Cancer; Gastro-Esophageal(GE) Junction Cancer; Gastrointenstinal Stromal Tumor (GIST); Colon/Rectal Cancer; Colon/Rectal Cancer Colon Cancer; Colon/Rectal Cancer Rectal Cancer; Colon/Rectal Cancer Anal Cancer; Anal Cancer; Hepatobiliary Cancers; Hepatobiliary Cancers Liver; Pancreatic Cancer

Summary: we have an active research program in gastrointestinal cancers including clinical trials, epidemiologic, and translational studies. we would like to establish a biospecimen bank linked to useful clinical information in order to learn more about diagnostic, predictive and prognostic markers for gastrointestinal cancers. primary objectives: 1. to collect and store tumor and normal tissue (previously collected paraffin embedded or frozen specimen) and blood in patients with gastrointestinal (gi) cancers. secondary objectives: 1. collect detailed clinical information via a patient questionnaire that includes demographic, socioeconomic, lifestyle, family, past medical, medication and cancer histories 2. collect details about the tumor specimen extracted from patient charts.


Eligibility criteria:
inclusion criteria:1. patients are eligible if they have a histologically proven gastrointestinal cancer (esophageal, gastroesophageal junction, gastric, small intestine, appendix, colon, rectum, anus, liver, gallbladder, bile ducts, pancreas, neuroendocrine, and gi stromal tumor). 2. 18 years of age or older 3. ability to understand and the willingness to sign a written informed consent document. exclusion criteria:none
shoulder rating questionnaire in turkish

Conditions: Shoulder Pain

Summary: the purpose of this study is to determine the turkish version of the shoulder rating questionnaire (srq) and assign reliability and validity in turkish patients.

shoulder pain is one of the common musculoskeletal disorders. a self- administered patient-based questionnaire has an important role for evaluate shoulder disabilities and also it is helpful for assess the treatment success.the purpose of this study is to determine the turkish version of the shoulder rating questionnaire (srq) and assign reliability and validity in turkish patients.the turkish version of the shoulder rating questionnaire (srq-t) will be applied to patients after translation from english into turkish. 122 patients will be participate to the study. patients who were over 18 years with various shoulder pain complaints will be included into the study. the patients with mixed-type pain, cancer pain, headache, substance abuse, severe depression and fibromyalgia syndrome will be excluded. the musculoskeletal and neurological examinations of the patients will be performed. the turkish version of the shoulder rating questionnaire (srq-t) and disabilities of arm, shoulder, hands-t (dash-t) will be applied to all patients. srq-t and dash-t will be collected in two sessions with at last three days between the sessions for pre-assessment and post-assessment. reliability of srq-t questionnaire will be tested by internal consistency and test-retest reliability. internal consistency will be evaluated by determining intraclass correlation coefficient (icc) with 95% confidence interval, ranged between 0 and 1. to determine the internal consistency of the five domains of srq-t, cronbach's alfa coefficient will be computed for both pre- and post-assessment of the questionnaire. the test-retest method with wilcoxon signed rank test will be used to determine reliability of srq-t and its domains. then, spearman correlation coefficients will be used to assess the discriminant validity of srq-t for evaluation of shoulder pain. the spearman correlation coefficient score more than 0.70 will be accepted for reliability

Eligibility criteria:
inclusion criteria: * patients who were over 18 years with various shoulder pain complaints exclusion criteria: * the patients with mixed-type pain, cancer pain, headache, substance abuse, severe depression and fibromyalgia syndrome

Keywords: disability evaluation shoulder pain shoulder validation studies outcome measures